New Zealand markets closed
  • NZX 50

    -166.38 (-1.40%)

    -0.0023 (-0.37%)

    -31.20 (-0.39%)
  • OIL

    -0.12 (-0.15%)
  • GOLD

    -16.10 (-0.69%)

Enzyme Replacement Therapy Market Size to Hit USD US$ 21.25 billion by 2030 | Growth Plus Reports

Growth Plus Reports
Growth Plus Reports

Newark, New Castle, USA, Feb. 09, 2023 (GLOBE NEWSWIRE) -- According to the latest report published by Growth Plus Reports, the global Enzyme Replacement Therapy Market is expected to clock US$ 21.25 billion by 2030 and to grow at a CAGR of 8.5% during the forecast period. Owing to the increasing prevalence of rare diseases and rising government initiatives for rare diseases. This exclusive information is published by Growth Plus Reports in its report titled “Enzyme Replacement Therapy Market – Global Outlook & Forecast 2022-2030”

Download PDF Brochure of Enzyme Replacement Therapy Market Size - COVID-19 Impact and Global Analysis with Strategic Developments at:

Market Drivers                                                        


Demand for enzyme replacement therapy (ERT) is primarily driven by an increase in the number of rare diseases that require novel treatment techniques, growth in the availability of enzyme replacement therapies, increased awareness, and relaxing rules for rare disease therapy. Increasing medical research and more knowledge regarding enzyme replacement therapies are predicted to be prevalent drivers driving global enzyme replacement therapy market (ERT) market expansion. The rising prevalence of rare diseases, as well as initiatives undertaken by the government and others, are projected to play a significant role in the expansion of the enzyme replacement therapy market. Lamzede, which is used to treat Alpha-mannosidosis, was approved for marketing in the European Union by the European Medicines Agency's (EMA) Committee for Medicinal Products for Human Use (CHMP) in 2019. According to EURORDIS, there are currently about 6,000 uncommon diseases in existence, with over 30 million Europeans affected. Furthermore, at least 80% of these rare diseases are chronic and potentially fatal. As a result, the treatment of rare disorders is critical, promoting the growth of the enzyme replacement therapy market.

Excerpts from ‘By Drug Class Segmentation’

Based on drug class, the global enzyme replacement therapy market has been segmented into:

  • Alglucosidasealfa

  • Agalsidase

  • Pancrelipase

  • Idursulfase

  • Laronidase

  • Imiglucerase

  • Elosulfasealfa

  • Asfotasealfa

  • Galsulfase

  • Velaglucerasealfa

  • Others

The agalsidase segment is the fastest growing segment during forecast period. Fabry is an X-linked uncommon disease that belongs to the lysosomal storage diseases group. Algasidase Alfa is a recombinant human a-galactosidase (AGAL) formulation that is used to treat Fabry disease. Shire, a subsidiary of Takeda Pharmaceutical Company, currently manufactures this enzyme under the brand name Replagal. Replagal has acquired marketing and production permission in Canada, the United Kingdom, and other regions of Europe. Furthermore, according to a report published in JIMD, Fabry disease is becoming increasingly common in the dialysis community in 2019. Fabry disease has been reported to affect approximately 1.2% of the dialysis population worldwide. As a result of the high frequency of Fabry disease, there is an increasing need for treatment, which is projected to drive the enzyme replacement therapy market in the algasidase alfa segment.

Excerpts from ‘By Region Segmentation’

Based on region, the global enzyme replacement therapy market has been segmented into

  • North America

  • Europe

  • Asia Pacific

  • Rest of the world

North America is likely to hold a significant market position in the global artificial disc market as a result of government and other organisations' initiatives connected to rare diseases and their treatment. The National Institutes of Health, for example, provided around USD 31 million in funding to 20 teams, including five new groups of scientists, clinicians, patients, families, and patients, to study a wide spectrum of rare diseases in 2019. An additional USD 7 million has been allocated to data coordinating centres to aid in research initiatives. Furthermore, the National Center for Advancing Translational Sciences (NCATS), one of the National Institutes of Health's centres, is entirely dedicated to the treatment of patients with rare conditions. Furthermore, the rising prevalence of rare illnesses is expected to stimulate the rise of enzyme replacement therapy in North America. According to the Genetic and Rare Diseases Information Center (GARD), rare diseases currently afflict between 25 and 35 million people in the United States.

During the projected period, Asia Pacific is expected to have a significant CAGR in the market. Market growth is being driven by the rise of healthcare behemoths in quickly growing economies such as China, India, and others. These global corporations are making large investments in the Asia Pacific region's healthcare sector.

Browse Full Report with Complete TOC @

Excerpts from ‘Competitive Landscape’

Some of the competitive players in the global enzyme replacement therapy market include:

  • Shire Plc

  • Sanofi S.A.

  • Genzyme Corporation

  • Biomarin Pharmaceutical Inc.

  • AbbVie

  • Alexion Pharmaceuticals Inc.

  • Pfizer Inc.

  • Leadiant Biosciences, Inc.

  • Allergan plc

  • Horizon Pharma Public Limited Company

  • Actelion (Janssen)

  • Takeda Pharmaceutical Company Limited

  • Protalix Biotherapeutics

  • Amicus Therapeutics

  • Johnson & Johnson Services Inc.

  • Recordati Rare Diseases

  • Protalix Biotherapeutics

  • Amicus Therapeutics, Inc.

Companies have been launching strategic initiatives connected to enzyme replacement therapy in order to expand their market presence. Takeda, for instance, recently displayed its latest developments in lysosomal storage disorders at the World Symposium in Orlando. Similarly, In June 2022, Recordati Rare Diseases has announced positive results from the Phase III Linc 4, Phase III Linc 3, and Illustrate ISTURISA investigations, which were presented at the ENDO 2022 symposium in Atlanta, Georgia. Most individuals tolerate this medication well and have no side effects.

Table of Content


    1. Market Ecosystem

    2. Timeline Under Consideration

      1. Historical Years - 2020

      2. Base Years - 2021

      3. Forecast Years – 2022 to 2030

    3. Currency Used in the Report


    1. Research Approach

    2. Data Collection Methodology

    3. Data Sources

      1. Secondary Sources

      2. Primary Sources

    4. Market Estimation Approach

      1. Bottom Up

      2. Top Down

    5. Market Forecasting Model

    6. Limitations and Assumptions       


    1. Current Market Trend (COVID-19 Perspective)

    2. Key Players & Competitive Positioning (2021)


    1. Drivers

    2. Restraints/Challenges

    3. Opportunities


    1. Alglucosidasealfa

    2. Agalsidase

    3. Pancrelipase

    4. Idursulfase

    5. Laronidase

    6. Imiglucerase

    7. Elosulfasealfa

    8. Asfotasealfa

    9. Galsulfase

    10. Velaglucerasealfa

    11. Others


    1. Parenteral

    2. Oral

TOC Continued..


  • Powered with Complimentary Analyst Hours and Expert Interviews with Each Report

  • Comprehensive quantitative and qualitative insights at segment and sub-segment level

  • Covid 19 impact trends and perspective

  • Granular insights at global/regional/country level

  • Deep-rooted insights on market dynamics (drivers, restraints, opportunities) and business environment

  • Blanket coverage on competitive landscape

  • Winning imperatives

  • Exhaustive coverage on 'Strategic Developments' registered by leading players of the market


  • Distributor Landscape Assessment

  • Pricing Intelligence

  • Customer Base Assessment

  • Investment & Initiatives Analysis

  • 'Business Profile' of Key Players

Schedule a call with our analyst:

Visit our report store at -

About Us:

Growth Plus Reports is part of GRG Health, a global healthcare knowledge service company. We are proud members of EPhMRA (European Pharmaceutical Marketing Research Association).

Growth Plus portfolio of services draws on our core capabilities of secondary & primary research, market modelling & forecasting, benchmarking, analysis and strategy formulation to help clients create scalable, ground-breaking solutions that prepare them for future growth and success.

We were awarded by the prestigious CEO Magazine as "Most Innovative Healthcare Market Research Company in 2020.

Manan Sethi
Director, Market Insights

256 Chapman Road

STE 105-4, Newark,

New Castle - 19702, USA
Phone no: +1 888 550 5009